Positioning Head Tilt in Canine Lysosomal Storage Disease: A Retrospective Observational Descriptive Study

Shinji Tamura 1*, Yumiko Tamura 1, Yuya Nakamoto 2,3, Daisuke Hasegawa 4, Masaya Tsuboi 5, Kazuyuki Uchida 5, Akira Yabuki 6 and Osamu Yamato 6*

1 Tamura Animal Clinic, Hiroshima, Japan, 2 Neuro Vets Animal Neurology Clinic, Kyoto, Japan, 3 Veterinary Surgery, Graduate School of Life and Environmental Science, Osaka Prefecture University, Sakai, Japan, 4 Laboratory of Veterinary Radiology, Nippon Veterinary and Life Science University, Tokyo, Japan, 5 Laboratory of Veterinary Pathology, Graduate School of Agriculture and Life Science, University of Tokyo, Tokyo, Japan, 6 Laboratory of Clinical Pathology, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan

Positioning head tilt is a neurological sign that has recently been described in dogs with congenital cerebellar malformations. This head tilt is triggered in response to head movement and is believed to be caused by a lack of inhibition of the vestibular nuclei by the cerebellar nodulus and ventral uvula (NU), as originally reported cases were dogs with NU hypoplasia. We hypothesized that other diseases, such as lysosomal storage diseases that cause degeneration in the whole brain, including NU, may cause NU dysfunction and positioning head tilt. Videos of the clinical signs of canine lysosomal storage disease were retrospectively evaluated. In addition, post-mortem NU specimens from each dog were histopathologically evaluated. Nine dogs were included, five with lysosomal storage disease, two Chihuahuas with neuronal ceroid lipofuscinosis (NCL), two Border Collies with NCL, one Shikoku Inu with NCL, two Toy Poodles with GM2 gangliosidosis, and two Shiba Inus with GM1 gangliosidosis. Twenty-eight videos recorded the clinical signs of the dogs. In these videos, positioning head tilt was observed in seven of nine dogs, two Chihuahuas with NCL, one Border Collie with NCL, one Shikoku Inu with NCL, one Toy Poodle with GM2 gangliosidosis, and two Shiba Inus with GM1 gangliosidosis. Neuronal degeneration and loss of NU were histopathologically confirmed in all diseases. As positioning head tilt had not been described until 2016, it may have been overlooked and may be a common clinical sign and pathophysiology in dogs with NU dysfunction.

Keywords: positioning head tilt, dog, lysosomal storage disease, ceroid lipofuscinosis, GM1 gangliosidosis, GM2 gangliosidosis, nodulus, ventral uvula

INTRODUCTION

The concept of positioning head tilt (PHT) as a neurological sign has recently been established. Dogs with this symptom can turn freely in any direction at their will. The head is in a normal position when static or when the dog walks straight forward. However, the head tilts to the opposite side when the dog turns; when the dog turns to the right, the left head tilt appears. Therefore,
the direction of head tilt changes every time the dog turns its head. This neurological sign is believed to occur in response to head movement and is caused by a lack of inhibition of the vestibular nuclei by the cerebellar nodulus and ventral uvula (NU) (1, 2). The original documented cases were three dogs with presumptive NU hypoplasia (1). Recently, PHT was observed in a dog with gliomatosis cerebri affecting NU (3–5). We hypothesized that other diseases, such as lysosomal storage diseases (LSDs) that cause degeneration in the whole brain, including the cerebellum, may also cause NU dysfunction and PHT. To verify this hypothesis, we reevaluated the clinical signs and histopathological changes in the NU of dogs with LSDs that we had previously encountered retrospectively.

**MATERIALS AND METHODS**

This is a retrospective, observational, descriptive study. Therefore, live animals were not used in this study, and ethical approval is not required due to their nature. However, all owners of the cases, including this study, received informed consent and had approved that their dogs and data would be used for academic research.

**Cases and Data Collection**

Stored videos recording neurological signs of canine cases with definitively diagnosed LSDs were collected from three veterinary clinics. Clinical data of those cases were collected, including breed, sex, age of clinical onset, age of death, method of definitive diagnosis, genetic mutation, magnetic resonance imaging (MRI), and tissue specimens of the cerebellum, including NU (Table 1).

**Included Cases**

Nine dogs were included in this study: two Chihuahuas with neuronal ceroid lipofuscinosis (NCL) (Cases 1 and 2), two Border Collies with NCL (Cases 3 and 4), one Shikoku Inu with NCL (Case 5), two Toy Poodles with GM2 gangliosidosis variant 0 (Sandhoff disease) (Cases 6 and 7), and two Shiba Inus with GM1 gangliosidosis (Cases 8 and 9). All affected dogs were definitively diagnosed by pedigree analysis, genetic testing, lysosomal enzyme activity, thin-layer chromatography, or histopathology (see individual references and Table 1). All dogs with each type of LSD included in this study have been previously published, and detailed clinical, imaging, and pathological findings and methodologies of various tests should be referred to in the literature (6–21). Clinical characteristics of each type of LSD are summarized below.

**NCL in Chihuahuas**

Clinical signs, including behavioral abnormalities such as signs of morbid fear or hyperacusis, visual impairment, and ataxia, began at 16–18 months of age and died of neurological deterioration at 23–24 months. This disease is an inherited disease characterized by lipopigment deposition in neurons and other cells of the body (6–9). This disease is caused by a mutation in the ceroid lipofuscinosis neuronal 7 (CLN7/MFSD8) gene (7). Detailed clinical, imaging, histological, and molecular characteristics have previously been reported (7–9).

**NCL in Border Collies**

Clinical signs, including behavioral abnormalities, began at 15–20 months of age and worsened progressively, with motor dysfunction, visual impairment, myoclonus/myoclonic seizure appearing at 19–23 months, and lethargy to death at 23–32 months. This disease is an inherited disease characterized by lipopigment deposition in neurons and other cells of the body. This disease is caused by a mutation in the ceroid lipofuscinosis neuronal 5 (CLN5) gene. Detailed clinical, imaging, histological, and molecular characteristics have previously been reported (6, 10, 11).

**NCL in Shikoku Inus**

Clinical signs, including gait abnormalities, ventral flexion of the neck, and postural nystagmus, began at 32 months of age and worsened progressively, with visual impairment appearing at 43 months and lethargy to euthanize at 68 months. This disease is characterized by the deposition of lipopigment in neurons and other cells in the body. This disease is predicted to be an inherited disease, but the causative mutation has not yet been identified. Detailed clinical, imaging, and histological characteristics have previously been reported (12).

**GM2 Gangliosidosis Variant 0 (Sandhoff Disease) in Toy Poodles**

Clinical signs, including motor disorders, ataxia, intention tremor, decreased corneal reflex, and absence of menace response, began at ∼9–12 months of age (6, 13, 14). The animals died of neurological deterioration at 18–23 months. This disease is an autosomal recessive deficiency of β-hexosaminidase A and B enzyme activity due to a frameshift mutation of the HEXB gene (14). Detailed clinical, imaging, histological, and molecular characteristics have previously been reported (6, 13, 14).

**GM1 Gangliosidosis in Shiba Inus**

Clinical signs, including cerebellar ataxia, began at 5–6 months of age and worsened progressively, with cerebral signs appearing at 7–8 months, atactic abasia or astasia at 9–10 months, and lethargy to death at ∼11 months (6, 15). This disease is an autosomal recessive deficiency of β-galactosidase enzyme activity due to a mutation of the GLBI gene (16). Detailed clinical, imaging, histological, and molecular characteristics have previously been reported (6, 15–22).

**Evaluation of Videos, MRIs, and Histopathology**

All videos stored of these dogs were carefully evaluated to determine whether the dogs showed PHT or not by three experienced veterinary neurologists (ST, YN, and DH) in the council system. The recorded timings of the videos for each case are summarized in Table 1. MRI of the brain was obtained with a 0.3-Tesla system (Airis II, Fujifilm Medical Systems, Tokyo, Japan) in Cases 1–7 and 9, and with a 1.5-Tesla system (Visart, Toshiba Corporation, Tokyo, Japan) in Case 8. Sagittal T2-weighted images of these cases were evaluated for cerebellar atrophy by
TABLE 1 | Summary of the cases studied.

| Case | Disease | Breed/sex | Type | Onset (months) | Age when videos are available (months) | Death (months) | Diagnosis | Gene | Mutation |
|------|---------|-----------|------|---------------|----------------------------------------|---------------|-----------|------|----------|
| 1    | NCL     | CH/M      | LJ   | 18            | 19, 22, 23                              | 24            | G, P      | MFSD8| chr19:13,010,759delT* |
| 2    | NCL     | CH/M      | LJ   | 16            | 18, 21                                  | 23E           | G, P      | MFSD8| chr19:13,010,759delT* |
| 3    | NCL     | BC/M      | LJ   | 16            | 16                                      | 25E           | G, P      | CLN5 | c.619C>T |
| 4    | NCL     | BC/F      | LJ   | 20            | 23                                      | 26            | G         | CLN5 | chr22:30,574,637C>T* |
| 5    | NCL     | Shikoku/M | A    | 32            | 35, 44, 46, 47, 49, 51, 53, 65, 68      | 68E           | P         | ND     | ND       |
| 6    | GM2     | TP/F      | LJ   | 12            | 21                                      | 21E           | G, P      | HEXB | chr2:57,225,684delG* |
| 7    | GM2     | TP/F      | LJ   | 11            | 16, 16.5, 17, 17.5, 18, 18.5, 19         | 23            | G, LE, TLC, P | HEXB | chr2:57,225,684delG* |
| 8    | GM1     | Shiba/M   | J    | 5             | 5, 7                                    | 11E           | G, P      | GLB1 | chr23:3,796,317delC* |
| 9    | GM1     | Shiba/F   | J    | 6             | 6, 9                                    | 12            | G         | GLB1 | chr23:3,796,317delC* |

NCL, neuronal ceroid-lipofuscinosis; GM2, GM2 gangliosidosis; GM1, GM1 gangliosidosis; CH, Chihuahua; BC, Border Collie; TP, Toy Poodle; M, male; F, female; LJ, late-juvenile; A, adult; J, juvenile; E, euthanasia; G, genetic test; P, pathology; LE, leucocyte enzyme activity; TLC, thin-layer chromatography; ND, not determined.

*CanFam 3.1.

three experienced veterinary neurologists (ST, YN, and DH) in the council system.

Brain tissue specimens of each disease (Cases 1, 3, 5, 7, and 9) were collected at necropsy, and the specimens were prepared by fixed and stored in 10% formalin. Paraffin-embedded tissue sections, including NU prepared by the standard method and stained with hematoxylin and eosin, were evaluated and compared to that of a normal control dog by veterinary neuropathologists (MT, KU).

RESULTS

Evaluation of Videos

Twenty-eight videos that recorded the clinical signs of the nine cases were available. The relationship between the approximate stages of disease (7, 10–13, 17) and the recorded time of each video is summarized in Figure 1. PHT was observed in two Chihuahuas with NCL (Cases 1 and 2), one Border Collie with NCL (Case 3), one Shikoku Inu with NCL (Case 5), one Toy Poodle with GM2 gangliosidosis (Case 7), and two Shiba Inus with GM1 gangliosidosis (Cases 8 and 9). In Case 1 (Chihuahua with NCL), PHT was slightly observed at 19 months of age and was relatively more significant at 22 months. A right-left directed abnormal repetition movement behavior, which elicited PHT every head turn, was observed at 23 months of age. In Case 3 (Border Collie with NCL), PHT was slightly observed at 16 months of age. In Case 5 (Shikoku Inu with NCL), PHT was clearly observed at 46 months of age and was once not observed and was again observed at 53 months. It was unobservable at 65 and 68 months, as the dog could not maintain the trunk position and recumbency. In Case 7 (Toy Poodle with GM2 gangliosidosis variant 0), PHT was not observed at 17 months of age but was relatively clearly observed at 18.5 months and was unobservable at 19 months as the dog recumbent. A slight PHT was observed in Case 9 (Shiba Inu with GM1 gangliosidosis) at 6 months of age and was unobservable at 9 months, as the dog was recumbent. The PHT of these dogs is shown in Figure 2, and the videos are included in Supplementary Videos 1, 2. The PHT in the other cases is summarized in Figure 1.

MRI Findings of NU

Widened fissures of the cerebellar vermis and dilated cerebrospinal fluid space between the cerebellum and brain stem, including the fourth ventricle, were observed in all cases on mid-sagittal T2-weighted MR images, indicating cerebellar atrophy (23–25). However, the details of abnormalities by region in the cerebellum were not clear (Figure 3).

Histopathological Findings of NU

Severe neuronal degeneration and neuronal loss were observed in the NU of Cases 1 (Chihuahua with NCL), 4 (Border Collie with NCL), 7 (Toy Poodle with GM2 gangliosidosis), and 8 (Shiba Inu with GM1 gangliosidosis). Neurons of the molecular, Purkinje, and granular layers are severely decreased throughout the cerebellum, and a variety of intracytoplasmic accumulations were observed in residual Purkinje cells, ceroid-lipofuscin-like materials in Cases 1 and 4, and pale eosinophilic granular materials in Cases 7 and 8, as described in previous reports (7, 10–13, 17). Severe astrogliosis and microgliosis were also observed in the cerebellar cortex. Although neuronal accumulation with ceroid-lipofuscin-like material was observed in the cerebellar neurons of Case 5 (Shikoku Inu with NCL), the pathological extent of neuronal loss appeared milder than in the other cases (Figure 4).
DISCUSSION

The present hypothesis that not only dogs with NU hypoplasia and tumors affecting NU but also with other diseases, such as LSD, which cause atrophy in the whole brain, may cause NU dysfunction and subsequent PHT, was partially verified in this study. Although cerebellar atrophy was observed in MR images in all cases, details by region in the cerebellum were unclear. However, neuronal degeneration and loss were observed histopathologically in the NU of all diseases in this study, and this is consistent with our previous hypothesis that NU dysfunction causes PHT (1, 2).

PHT observed in the videos of dogs with LSDs discussed in this study was not noticed during consultation (7, 10–13, 17). There were several reasons for this. First, the lack of recognition of this neurological sign until originally described in 2016 is the most common reason. Other reasons include its slightness in some cases, changing the tilt side frequently, and distraction by well-known signs such as intention tremor and ataxia.

The head tilt was slightly to moderate in Chihuahuas with NCL, a Border Collie with NCL, and a Shiba Inu with GM1 gangliosidosis, while it was clearly observed in a Toy Poodle with GM2 gangliosidosis and a Shikoku Inu with NCL. In contrast, neural degeneration and loss were slightly observed in Shikoku Inu with NCL, although severe in other cases. Therefore, the correlation between the degree of head tilt and the pathological severity is unclear. PHT was observed once and then disappeared in Shikoku Inu with NCL in this study. Although the reason was unknown, PHT is reported to be sometimes compensated (1). It may be compensated for its much slower progression in a Shikoku Inu with NCL than in other diseases. Recently, intermittent head tilt was reported in Chihuahua with NCL (9), which may also be PHT.

The limitations of this study include the retrospective review of available videos that were shot without recognition of PHT, the small number of cases, and the inclusion of only dogs. However, it is important that PHT is also observed in some dogs with LSDs. PHT may not be observed in some videos because the dog did not turn the head properly during the recording period. Although PHT was not observed in the videos of the late stage in which the dog could not maintain the trunk position and recumbency, it might be observed in those stages with support to maintain trunk position and turn the dogs’ heads side to side as when we evaluate physiological nystagmus. The observers may have been biased when asked to look for an intermittent clinical sign such as PHT in a short video clip. Another limitation include that histopathological changes observed not only in the nodulus and ventral uvula but also whole cerebellum, so it did not confirm the previous suspicion that PHT is related to this specific region. It is
FIGURE 2 | Positioning head tilt observed in dogs with lysosomal storage diseases. The heads of all dogs tilt to opposite sides when turning to one side. (A) A Chihuahua with neuronal ceroid lipofuscinosis (NCL) (Case 1, 19 months of age); (B) a Border Collie with NCL (Case 3, 16 months of age); (C) a Shikoku Inu with NCL (Case 5, 46 months of age); (D) a Toy Poodle with GM2 gangliosidosis variant 0 (Sandhoff disease) (Case 7, 18 months of age); (E) a Shiba Inu with GM1 gangliosidosis (Case 9, 6 months of age).

FIGURE 3 | Mid-sagittal T2-weighted MR images of five lysosomal storage diseases. (A) A Chihuahua with NCL (Case 1, 19 months of age), (B) a Border Collie with NCL (Case 3, 16 months of age), (C) a Shikoku Inu with NCL (Case 5, 46 months of age), (D) a Toy Poodle with GM2 gangliosidosis variant 0 (Sandhoff disease) (Case 7, 21 months of age), (E) a Shiba Inu with GM1 gangliosidosis (Case 8, 11 months of age). Atrophy of the whole brain, including the cerebellum, is observed in all cases.
unclear whether lesions in other areas of the cerebellum cause PHT.

CONCLUSION

PHT was observed not only in dogs with NU hypoplasia and tumors affecting NU reported previously but also in several LSDs in this study. As PHT had not been described until 2016, it might have been overlooked in some veterinary patients. The clinical sign described as "alternating head tilt" in a dog with a tumor, including NU (3), was recognized as PHT (5) only after it was pointed out that it might be PHT (4). Although further observation of many cases with cerebellar diseases that cause NU dysfunction, including vascular diseases, inflammatory diseases, and trauma, is required, PHT may be a common clinical sign and pathophysiology in dogs with NU dysfunction.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

This is a retrospective observational descriptive study. Therefore, live animals were not used in this study, and the ethical approval is not required due to its nature. However, all owners of cases including this study received an informed consent and had approved that their dogs and data would be used for academic researches. Written informed consent for participation was not obtained from the owners because each case was individually published in papers with written or verbal informed consent at the time. Some of the cases do not have written informed consent, but it is not possible to obtain it because a long time (more than 10 years) has passed and we have not been in contact with each of them since then.

AUTHOR CONTRIBUTIONS

ST, YT, YN, and DH participated in clinical case management. MT and KU participated in the pathological examination. ST drafted the manuscript. ST, YN, and DH reviewed the stored videos and MRI data. YT, YN, DH, AY, and OY participated in the review and editing of the manuscript. All authors contributed to the article and approved the submitted version.
SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2021.802668/full#supplementary-material

Supplementary Video 1 | Edited video of positioning head tilts observed in dogs with lysosomal storage diseases. Chihuahua with neuronal ceroid lipofuscinosis

Supplementary Video 2 | Shiba Inu with GM1 gangliosidosis (Case 9, 6 months of age).

REFERENCES

1. Tamura S, Nakamoto Y, Uemura T, Tamura Y. Head tilting elicited by head turning in three dogs with hypoplastic cerebellar nodulus and ventral uvula. Front Vet Sci. (2016) 3:104. doi: 10.3389/fvets.2016.00104
2. Tamura S. Commentary: transient postural vestibulo-cerebellar syndrome in three dogs with presumed cerebellar hypoplasia. Front Vet Sci. (2021) 8:613521. doi: 10.3389/fvets.2021.613521
3. Liatsis T, Hammond G, Chapman GE, Cloquell Miro A, Stalin C, Gutierrez-Quintana R. MRI findings in a young dog with gliomatosis cerebri. J Small Anim Pract. (2021) online ahead of print. doi: 10.1111/jasp.13394
4. Tamura S. Was the “alternating head tilt” a “positioning head tilt”? J Small Anim Pract. (2021) In press. doi: 10.1111/jasp.13447. [Epub ahead of print].
5. Liatsis T, Gutierrez-Quintana R. Response to: was the “alternating head tilt” “positioning head tilt”? J Small Anim Pract. (2021) online ahead of print. doi: 10.1111/jasp.13427
6. Hasegawa D, Tamura S, Nakamoto Y, Matsuki N, Takahashi K, Fujita M, et al. Magnetic resonance findings of the corpus callosum in canine and feline lysosomal storage diseases. PLoS ONE. (2013) 8:e83455. doi: 10.1371/journal.pone.0083455
7. Ashwini A, D’Angelo A, Yamato O, Giordano C, Cagnotti G, Harcourt-Brown T, et al. Neuronal ceroid lipofuscinosis associated with an MFSD8 mutation in Chihuahuas. Mol Genet Metab. (2016) 118:326–32. doi: 10.1016/j.ymgme.2016.05.008
8. Nakamoto Y, Yamato O, Uchida K, Nibe K, Tamura S, Ozawa T, et al. Neuronal ceroid-lipofuscinosis in long-haired Chihuahuas: clinical, pathologic, and MRI findings. J Am Anim Hosp Assoc. (2011) 47:e64–70. doi: 10.5326/JAAHA-MS-5564
9. Faller KME, Bras J, Sharpe SJ, Anderson GW, Darwent L, Kun-Rodrigues C, et al. The Chihuahua dog: a new animal model for neuronal ceroid lipofuscinosis CLN7 disease? J Neurosci Res. (2016) 94:339–47. doi: 10.1002/jnr.23710
10. Koie H, Shibuya H, Sato T, Sato A, Nawa K, Nawa Y, et al. Magnetic resonance imaging of neuronal ceroid lipofuscinosis in a Border Collie. J Vet Med Sci. (2004) 66:1453–6. doi: 10.1292/jvms.66.1453
11. Mizukami K, Kawamichi T, Koie H, Tamura S, Matsunaga S, Imamoto S, et al. Neuronal ceroid-lipofuscinosis in Border Collie dogs in Japan: clinical and molecular epidemiological study (2000–2011). Sci World J. (2012) 2012:383174. doi: 10.1100/2012/383174
12. Tamura S, Tsuibo M, Ueoka N, Doi S, Tamura Y, Uchida K, et al. Adult-onset neuronal ceroid lipofuscinosis in a Shikoku Inu. Vet Sci. (2021) 8:227. doi: 10.3390/vets8002227
13. Tamura S, Tamura Y, Uchida K, Nibe K, Nakaichi M, Hossain MA, et al. GM2 gangliosidosis variant 0 (Sandhoff-like disease) in a family of toy poodles. J Vet Intern Med. (2010) 24:1013–9. doi: 10.1111/j.1939-1676.2010.05064.x
14. Rahman MM, Chang HS, Mizukami K, Hossain MA, Yabuki A, Tamura S, et al. A frameshift mutation in the canine HEXB gene in toy poodles with GM2 gangliosidosis variant 0 (Sandhoff disease). Vet J. (2012) 194:412–6. doi: 10.1016/j.tvjl.2012.05.021
15. Yamato O, Ochiai K, Masuoka Y, Hayashida E, Tajima M, Omae S, et al. GM1 gangliosidosis in shiba dogs. Vet Rec. (2000) 146:493–6. doi: 10.1136/vr.146.17.493
16. Yamato O, Endoh D, Kobayashi A, Masuoka Y, Yonemura M, Hatakeyama A, et al. A novel mutation in the gene for canine acid β-galactosidase that causes GM1-gangliosidosis in Shiba dogs. J Inherit Metab Dis. (2002) 25:525–6. doi: 10.1023/A:1021280007739
17. Yamato O, Masuoka Y, Yonemura M, Hatakeyama A, Satoh H, Kobayashi A, et al. Clinical and clinico-pathologic characteristics of Shiba dogs with a deficiency of lysosomal acid β-galactosidase: a canine model of human GM1 gangliosidosis. J Vet Med Sci. (2005) 63:213–7. doi: 10.1292/jvms.63.213
18. Yamato O, Kobayashi A, Satoh H, Endoh D, Shoda T, Masuoka Y, et al. Comparison of polymerase chain reaction-restriction fragment length polymorphism assay and enzyme assay for diagnosis of GMI-gangliosidosis in Shiba dogs. J Vet Diagn Invest. (2004) 16:299–304. doi: 10.1177/10463870401600407
19. Nagayasu A, Nakamura T, Yamato O, Tsuzuki K, Hosaka Y, Ueda H, et al. Morphological analysis of corneal opacity in Shiba dog with GM1 gangliosidosis. J Vet Med Sci. (2008) 70:881–6. doi: 10.1292/jvms.70.881
20. Yamato O, Jo EO, Chang HS, Satoh H, Shoda T, Sato R, et al. Molecular screening of canine GM1 gangliosidosis using blood smear specimens after prolonged storage: detection of carriers among Shiba dogs in northern Japan. J Vet Diagn Invest. (2008) 20:68–71. doi: 10.1177/10463870802000113
21. Rahman MM, Kawaguchi H, Miyoshi N, Yabuki A, Nakamoto Y, Ozawa T, et al. Pathological features of salivary gland cysts in a Shiba dog with GM1 gangliosidosis: a possible misdiagnosis as malignancy. J Vet Med Sci. (2012) 74:485–9. doi: 10.1292/jvms.11-0309
22. Hasegawa D, Yamato O, Nakamoto Y, Ozawa T, Yabuki A, Itamoto K, et al. Serial MRI features of canine GM1 gangliosidosis: a possible imaging biomarker for diagnosis and progression of the disease. Sci World J. (2012) 2012:250197. doi: 10.1100/2012/250197
23. Van der Merwe LL, Lane E. Diagnosis of cerebellar cortical degeneration in a Scottish Terrier using magnetic resonance imaging. J Small Anim Pract. (2001) 42:409–12. doi: 10.1111/j.1748-5827.2001.tb0491x
24. Olby N, Blot S, Thibaud J-L, Phillips J, O'Brien DP, Burr J, et al. Cerebellar cortical degeneration in adult American Staffordshire Terriers. J Vet Intern Med. (2004) 18:201–8. doi: 10.1111/j.1939-1676.2004.tb01616.x
25. Tatalick LM, Marks SL, Baszler TV. Cerebellar atrophy characterized by granular cell loss in a Brittany. Vet Pathol. (1993) 30:385–8. doi: 10.1177/0300985893030000411

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Tamura, Tamura, Nakamoto, Hasegawa, Tsuibo, Uchida, Yabuki and Yamato. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.